| Gerald A Battersby, MD | |
|
9961 Sierra Ave, Fontana, CA 92335-6720 | |
| (909) 427-3910 | |
| Not Available |
| Full Name | Gerald A Battersby |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Hematology & Oncology |
| Location | 9961 Sierra Ave, Fontana, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467511030 | NPI | - | NPPES |
| 00A301690 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | A30169 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Gerald A Battersby, MD 393 E Walnut St, 3rd Floor Phr Systems, Pasadena, CA 91188-0001 Ph: (626) 405-3640 | Gerald A Battersby, MD 9961 Sierra Ave, Fontana, CA 92335-6720 Ph: (909) 427-3910 |
News Archive
After beginning treatment with remdesivir for COVID-19, a patient experienced significant bradycardia, or low heart rate. Her physicians used a dopamine infusion to stabilize her through the five-day course of remdesivir treatment, and her cardiac condition resolved itself at the end of the treatment.
This year's flu season is in full swing with 41 states now reporting widespread illness. Unfortunately, not enough children are getting the flu shot even though health officials recommend that all children 6 months and older get the vaccine. According to a new study by researchers at Wake Forest Baptist Medical Center, less than 45 percent of children were vaccinated against the flu during a five-year study period.
The successful implementation of "lean manufacturing" in various fields has inspired many businesses to adopt this model in their laboratories as well. However, laboratories have different challenges compared to manufacturing environments.
Endo Pharmaceuticals has submitted a complete response to the U.S. Food and Drug Administration (FDA) following the company's receipt of a Complete Response letter in October 2009 related to the New Drug Application (NDA) submission for FORTESTA™ (testosterone) 2% gel. The company's Class 2 resubmission is the next step in its intention to offer FORTESTA as a treatment option in the United States for men diagnosed with low testosterone (Low T), also known as hypogonadism. The FDA's review period for Class 2 resubmissions typically is six months.
Akorn, Inc. a specialty pharmaceutical company, today reported financial results for the third quarter ended September 30, 2009.
› Verified 4 days ago
Nainesh K. Gandhi, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 9985 Sierra Ave, Fontana, CA 92335 Phone: 866-454-3485 | |
Blanca E. Viramontes, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-427-3910 | |
Dr. Paymon Mesgarzadeh, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 9985 Sierra Ave, Fontana, CA 92335 Phone: 909-427-5000 | |
Kathryn Chang Lin, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 16465 Sierra Lakes Pkwy, Ste 245, Fontana, CA 92336 Phone: 909-829-7337 Fax: 909-829-1218 | |
Lih-jiau Chen, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-427-3910 | |
Tommy Tiong Hien Oei, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-427-3910 | |
Edmond C. Hui, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 9961 Sierra Ave, Fontana, CA 92335 Phone: 909-427-3910 |